Novel-fosfamide monotherapy or in combination with doxorubicin versus doxorubicin alone in patients with advanced soft tissue sarcoma: A pooled analysis of randomized clinical trials

BACKGROUND: Novel-fosfamides (NFOs) belong to active metabolites of ifosfamide that bypass the generation of toxic byproducts. In this analysis, we aimed to comprehensively assess the benefits and risks of NFO monotherapy or in combination with doxorubicin (DOX) versus single-drug DOX in previously...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xin-Xiu, Han, Yan-Hong, Kuang, Bo-Hua, Lin, Guo-He, Wang, Bi-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443742/
https://www.ncbi.nlm.nih.gov/pubmed/37603507
http://dx.doi.org/10.1097/MD.0000000000034902

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443742/
https://www.ncbi.nlm.nih.gov/pubmed/37603507
http://dx.doi.org/10.1097/MD.0000000000034902

Ejemplares similares